AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19438956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioceramic molecular impregnated treatment (Ossean®)
Number of subjects: 10
Study 19438956 — intervention group
Group type: COMPARATOR
Intervention: Dual acid-etched (DAE) surface
Number of subjects: 10
Study 17996241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg niacin for 6 weeks
Number of subjects: 20
Study 15893402 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated alpha-interferon combined with lamivudine
Number of subjects: 20
Study 15893402 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 11883552 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg B‐6
Number of subjects: 12
Study 11883552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11883552 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg B‐6
Number of subjects: 12
Study 10618689 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 114
Study 10618689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 114
Study 10618689 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 114
Study 10618689 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 114
Study 7488415 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV (doxorubicin 50 mg/m2, vincristine 2 mg i.v. on day 1, cyclophosphamide 800 mg/m2 on day 1)
Number of subjects: 81
Study 7488415 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE (doxorubicin 50 mg/m2, vincristine 2 mg i.v. on day 1, etoposide 60 mg/m2 i.v. on day 1 and 120 mg/m2 orally on days 2-5)
Number of subjects: 81
Study 7488415 — intervention group
Group type: COMPARATOR
Intervention: CAV
Number of subjects: 81
Study 7488415 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE
Number of subjects: 81
Study 2009895 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.d.
Number of subjects: 163
Study 2009895 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine s.r. 20 mg b.d.
Number of subjects: 163
Study 2009895 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 163
Study 2009895 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 163
Study 6616116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (drug)
Number of subjects: 0
Study 6616116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 6616116 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 6616116 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic subjects
Number of subjects: 0
Study 30406492 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual intervention (six 45-minute sessions over 2 weeks)
Number of subjects: 71
Study 30406492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 71
Study 29035597 — intervention group
Group type: EXPERIMENTAL
Intervention: CQA coffee (300 ml/day for 2 weeks)
Number of subjects: 15
Study 29035597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 ml/day for 2 weeks)
Number of subjects: 15
Study 26730967 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight storage in water with a cleansing tablet
Number of subjects: 13
Study 26730967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic cleaning and immersion in water with a cleansing tablet
Number of subjects: 13
Study 26730967 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing and immersion in water with a cleansing tablet
Number of subjects: 13
Study 26730967 — intervention group
Group type: COMPARATOR
Intervention: Brushing and immersion in water without a cleansing tablet
Number of subjects: 13
Study 24144876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (ivMP)
Number of subjects: 49
Study 24144876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (oMP)
Number of subjects: 49
Study 22304681 — intervention group
Group type: COMPARATOR
Intervention: Transdermal testosterone patch
Number of subjects: 0
Study 22304681 — intervention group
Group type: COMPARATOR
Intervention: Testosterone gel
Number of subjects: 0
Study 19848045 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (once-daily)
Number of subjects: 6500
Study 17898252 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric bladder ultrasonography (US)
Number of subjects: 93
Study 17898252 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheterization
Number of subjects: 93
Study 16244196 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric quadriceps training on a decline board
Number of subjects: 20
Study 16244196 — intervention group
Group type: COMPARATOR
Intervention: Concentric quadriceps training on a decline board
Number of subjects: 20
Study 11923038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (760 calories)
Number of subjects: 40
Study 11923038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (non-cheese pizza)
Number of subjects: 40
Study 11923038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with vitamin E (800 IU) and ascorbic acid (1,000 mg)
Number of subjects: 40
Study 11923038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal with vitamin E (800 IU) and ascorbic acid (1,000 mg)
Number of subjects: 40
Study 11923038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 40
Study 11923038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 40
Study 9577931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electromagnetic fields (50 Hz) of 0.2 microT-6.6 microT
Number of subjects: 13
Study 9577931 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to low-frequency electromagnetic fields (50 Hz)
Number of subjects: 13
Study 8126869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized grafts
Number of subjects: 49
Study 8126869 — intervention group
Group type: COMPARATOR
Intervention: Control grafts (untreated polytetrafluoroethylene prosthesis)
Number of subjects: 49
Study 8126869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized group
Number of subjects: 49
Study 8126869 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 2817745 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 35
Study 236528 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 12
Study 236528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 12
Study 236528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31175963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile cooperation intervention
Number of subjects: 52
Study 27815524 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic adherence monitoring with daily reminder alarms and feedback in the clinic regarding ICS use
Number of subjects: 90
Study 27815524 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm with adherence monitoring alone
Number of subjects: 90
Study 26527777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Vismodegib (GV)
Number of subjects: 106
Study 26527777 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus Placebo (GP)
Number of subjects: 106
Study 26527777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GV and GP
Number of subjects: 106
Study 22910302 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide slow release 1.5mg ± perindopril 2‐4 mg
Number of subjects: 3845
Study 22910302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3845
Study 21546378 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaparoscopic hernia repair using 2‐mm instrument sets and small diameter scopes
Number of subjects: 100
Study 19451556 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan, 80 mg/d (n = 2954)
Number of subjects: 5927
Study 19451556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 2972)
Number of subjects: 5927
Study 19451556 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 5927
Study 19451556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5927
Study 16709650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex + Lo CHO
Number of subjects: 18
Study 16709650 — intervention group
Group type: COMPARATOR
Intervention: Lo CHO
Number of subjects: 18
Study 16709650 — intervention group
Group type: COMPARATOR
Intervention: Ex + Norm CHO
Number of subjects: 18
Study 16709650 — intervention group
Group type: COMPARATOR
Intervention: Norm CHO
Number of subjects: 18
Study 15462099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1,25(OH)2D3 therapy (1-2 microg thrice a week for 12 weeks, mean dose 4.5 microg/week)
Number of subjects: 8
Study 15462099 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 healthy volunteers matched for age, sex, and BMI)
Number of subjects: 8
Study 16420079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) alone
Number of subjects: 102
Study 16420079 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo with response prevention (ERP) alone
Number of subjects: 102
Study 16420079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with fluvoxamine
Number of subjects: 102
Study 10357748 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplements containing 60 mg Fe, 250 microg folate, and 15 mg Zn
Number of subjects: 1295
Study 10357748 — intervention group
Group type: COMPARATOR
Intervention: Prenatal supplements containing 60 mg Fe and 250 microg folate without Zn
Number of subjects: 1295
Study 7580187 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately suprathreshold ECT (2.5T)
Number of subjects: 25
Study 7580187 — intervention group
Group type: COMPARATOR
Intervention: Barely suprathreshold ECT (T)
Number of subjects: 25
Study 2272864 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 60
Study 2272864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 60
Study 6153164 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct fluorescent antibody technique
Number of subjects: 19
Study 6153164 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS staining
Number of subjects: 19
Study 6153164 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (H & E, Trichrome, PTAH)
Number of subjects: 19
Study 6153164 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect fluorescent antibody technique (ethanol-fixed tissues)
Number of subjects: 19
Study 6153164 — intervention group
Group type: COMPARATOR
Intervention: Indirect fluorescent antibody technique (formalin-fixed tissues)
Number of subjects: 19
Study 6153164 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole treatment
Number of subjects: 19
Study 30760655 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 41
Study 30760655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RDN and crossover group
Number of subjects: 41
Study 30760655 — intervention group
Group type: COMPARATOR
Intervention: Control (standard pharmacologic therapy)
Number of subjects: 41
Study 27932292 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated Compression Stockings (GCS)
Number of subjects: 18
Study 27932292 — intervention group
Group type: COMPARATOR
Intervention: Placebo sock
Number of subjects: 18
Study 27588209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol dark chocolate (HFDC; 1064mg of flavanols/day)
Number of subjects: 32
Study 27588209 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol dark chocolate (LFDC; 88mg of flavanols/day)
Number of subjects: 32
Study 27588209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol dark chocolate (HFDC)
Number of subjects: 32
Study 24831394 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol/ipratropium
Number of subjects: 30
Study 24831394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22518045 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in consent approach
Number of subjects: 1129
Study 22518045 — intervention group
Group type: COMPARATOR
Intervention: Opt-out consent approach
Number of subjects: 1129
Study 22518045 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 1129
Study 19170904 — intervention group
Group type: EXPERIMENTAL
Intervention: RVOT
Number of subjects: 87
Study 19170904 — intervention group
Group type: COMPARATOR
Intervention: RVA
Number of subjects: 87
Study 17479527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for 24 weeks
Number of subjects: 24
Study 17479527 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control (APC) for 24 weeks
Number of subjects: 24
Study 15611537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA) with morphine
Number of subjects: 86
Study 15611537 — intervention group
Group type: COMPARATOR
Intervention: Nurse delivered analgesia with morphine via conventional route
Number of subjects: 86
Study 12522833 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 27
Study 12522833 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 9658759 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of alcoholic liver disease
Number of subjects: 22
Study 9658759 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schistosomiasis Japonica infection
Number of subjects: 22
Study 9658759 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Budd-Chiari syndrome
Number of subjects: 22
Study 9658759 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients positive for anti-HBc antibody
Number of subjects: 22
Study 9658759 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients positive for autoantibodies
Number of subjects: 22
Study 9658759 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic examination of liver
Number of subjects: 22
Study 7641721 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil bolus (30 micrograms kg-1) followed by infusion of placebo (group II)
Number of subjects: 100
Study 7641721 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion at the rate of 10 micrograms kg-1 h-1 (group III)
Number of subjects: 100
Study 7641721 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion at the rate of 20 micrograms kg-1 h-1 (group IV)
Number of subjects: 100
Study 7641721 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion at the rate of 40 micrograms kg-1 h-1 (group V)
Number of subjects: 100
Study 7641721 — intervention group
Group type: COMPARATOR
Intervention: Placebo bolus followed by placebo infusion (group I)
Number of subjects: 100
Study 7641721 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (any dosage) during abdominal surgery
Number of subjects: 100
Study 2666710 — intervention group
Group type: EXPERIMENTAL
Intervention: Finoptin (10 mg intravenous)
Number of subjects: 47
Study 2666710 — intervention group
Group type: COMPARATOR
Intervention: Phosphobion (10 mg)
Number of subjects: 47
Study 2666710 — intervention group
Group type: EXPERIMENTAL
Intervention: Finoptin
Number of subjects: 47
Study 2666710 — intervention group
Group type: COMPARATOR
Intervention: Phosphobion
Number of subjects: 47
Study 2666710 — intervention group
Group type: EXPERIMENTAL
Intervention: Finoptin and Phosphobion
Number of subjects: 47
Study 31945069 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages reminding respondents of familial support
Number of subjects: 0
Study 31945069 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of additional visual information
Number of subjects: 0
Study 30508547 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg secukinumab
Number of subjects: 0
Study 30508547 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg secukinumab
Number of subjects: 0
Study 30508547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28212060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 542
Study 28212060 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or vinflunine)
Number of subjects: 542
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: RawBMD
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: TPerc
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: RawT
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: TSamp
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: TRef
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline (CB)
Number of subjects: 774
Study 25749740 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage change from baseline (%CB)
Number of subjects: 774
Study 25092484 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes PULSE Programme for Men (6-month, self-administered, gender-tailored lifestyle intervention)
Number of subjects: 0
Study 25092484 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes PULSE Programme for Men
Number of subjects: 0
Study 25092484 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 22980300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 1059
Study 22980300 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1059
Study 19559374 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiotherapy
Number of subjects: 0
Study 19559374 — intervention group
Group type: COMPARATOR
Intervention: Salvage radiotherapy
Number of subjects: 0
Study 19559374 — intervention group
Group type: COMPARATOR
Intervention: Immediate postoperative or salvage radiotherapy with androgen deprivation therapy
Number of subjects: 0
Study 17562639 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-delivered foot reflexology
Number of subjects: 86
Study 17562639 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus attention (control)
Number of subjects: 86
Study 15155330 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 20 mg
Number of subjects: 43
Study 15155330 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 microg/kg
Number of subjects: 43
Study 11252624 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear mixed model (GLMM) methodology with Cox partial likelihood for survival analysis.
Number of subjects: 0
Study 11252624 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual maximum likelihood (REML) estimators of the variance component.
Number of subjects: 0
Study 9486490 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. tacrolimus
Number of subjects: 31
Study 9486490 — intervention group
Group type: EXPERIMENTAL
Intervention: p.o. tacrolimus
Number of subjects: 31
Study 9486490 — intervention group
Group type: COMPARATOR
Intervention: methylprednisolone or methotrexate co-administration
Number of subjects: 31
Study 7993858 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfused group
Number of subjects: 131
Study 7993858 — intervention group
Group type: COMPARATOR
Intervention: Nonblood transfused group
Number of subjects: 131
Study 2666662 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 electroacupuncture (10 Hz applied for 5 min)
Number of subjects: 130
Study 2666662 — intervention group
Group type: COMPARATOR
Intervention: Dummy acupuncture (ACP) point
Number of subjects: 130
Study 4706914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (12 g)
Number of subjects: 14
Study 4706914 — intervention group
Group type: COMPARATOR
Intervention: Lignin
Number of subjects: 14
Study 31512497 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI-613 plus modified FOLFIRINOX (mFFX)
Number of subjects: 0
Study 31512497 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRINOX (FFX)
Number of subjects: 0
Study 28385654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative Rehabilitation Program (PRP) for one week (IG)
Number of subjects: 80
Study 28385654 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative preparation for one week (CG)
Number of subjects: 80
Study 26366058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR (60 mg every 28 days)
Number of subjects: 88
Study 26366058 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR (40 mg every 28 days)
Number of subjects: 88
Study 26366058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Number of subjects: 88
Study 26366058 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 88
Study 23800793 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA) over the left swallowing motor cortex
Number of subjects: 21
Study 23800793 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA) over the right swallowing motor cortex
Number of subjects: 21
Study 23800793 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study 21665191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 204
Study 21665191 — intervention group
Group type: COMPARATOR
Intervention: Talking control (TC)
Number of subjects: 204
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 nmol kg(‐1) PP
Number of subjects: 26
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 nmol kg(‐1) PYY(3‐36)
Number of subjects: 26
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 nmol kg(‐1) PP+3 nmol kg(‐1) PYY(3‐36)
Number of subjects: 26